![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.00 | 54.55% | 34.00 | 33.00 | 35.00 | 37.50 | 22.50 | 22.50 | 704,530 | 16:26:34 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -3.14 | 14.52M |
RNS Number:1494J Celsis International PLC 01 March 2005 CELSIS INTERNATIONAL PLC Non-Executive Director Change 1 March 2005: Celsis International plc ("Celsis" or the "Company"), the microbial detection and analytical services company, today announces that Dr Peter Grant will stand down as non-executive director of the Board with immediate effect. Dr Grant leaves Celsis to pursue his career as Operations Director of the recently floated Biofusion plc. He has served as non-executive director of the Company since May 2002, prior to this he was an executive director since Celsis floated on the London Stock Exchange in 1993. Jack Rowell, Non-Executive Chairman of Celsis, commented: "We are extremely grateful to Peter for the significant contribution he has made to the formation and development of Celsis, both in his capacity of executive and non-executive director, over the last 12 years. As a founding director of Celsis, Dr Grant was responsible for developing the technology base from concept to product and was instrumental in growing Celsis into the successful company that it is today. On behalf of the Board we wish Peter well in his future career and thank him for his commitment to Celsis." Enquiries: Celsis International plc Tel: 01638 600 151 Jay LeCoque, Chief Executive Officer Jenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113 Ben Atwell Lucy Briggs Notes to editors Celsis International plc Celsis International plc is a microbial detection and analytical services company operating through two divisions, the Product Group and the Laboratory Group. Using its proprietary enzyme technology, the Product Group is the world leader in the provision of diagnostic systems for the rapid detection of microbial contamination. It works in close collaboration with many of the world's leading pharmaceutical, personal care and beverage companies, ensuring the safety and quality of products bound for consumers. The Laboratory Group provides outsourced analytical testing services to pharmaceutical companies to ensure the stability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisions have the capacity to deliver substantial cost savings to Celsis' customers. By reducing the time it takes to test and release raw materials and finished goods to the market place, Celsis' products facilitate increased manufacturing productivity and improved supply chain management. Celsis International plc is listed on the London Stock Exchange (CEL.L). Further information can be found on the Company's website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange END BOAPKFKPOBKDNBB
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions